Clinical Trial Update: Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating isavuconazole (BAL8557) for candidemia and invasive candidiasis; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidemia
• Invasive Candidiasis

Drugs mentioned

• Isavuconazole (Isavuconazole)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Candidiasis, Invasive, Candidemia | Phase 3 | Status: COMPLETED | Results posted: 2017-08-01